Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

por Ellmark, Peter, Mangsbo, Sara M., Furebring, Christina, Norlén, Per, Tötterman, Thomas H.
Publicado 2016

Pre-clinical development of the human CD40 agonistic antibody ADC-1013

por Norlén, Per, Veitonmäki, Niina, Smith, Karin Enell, Tötterman, Thomas H, Mangsbo, Sara M, Furebring, Christina, Ellmark, Peter
Publicado 2015

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer

por Mangsbo, Sara M, Broos, Sissela, Gustafsson, Erika, Furebring, Christina, Veitonmäki, Niina, Dahlen, Eva, Norlen, Per, Lindstedt, Malin, Tötterman, Thomas, Ellmark, Peter
Publicado 2013

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice

por Mangsbo, Sara M, Veitonmäki, Niina, Gustfson, Erika, Smith, Karin Enell, Furebring, Christina, Norlén, Per, Lindstedt, Malin, Tötterman, Thomas H, Ellmark, Peter
Publicado 2014

Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis

por Greiff, Lennart, Cervin, Anders, Ahlström-Emanuelsson, Cecilia, Almqvist, Gun, Andersson, Morgan, Dolata, Jan, Eriksson, Leif, Högestätt, Edward, Källén, Anders, Norlén, Per, Sjölin, Inga-Lisa, Widegren, Henrik
Publicado 2012

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

por Kvarnhammar, Anne Månsson, Veitonmäki, Niina, Hägerbrand, Karin, Dahlman, Anna, Smith, Karin Enell, Fritzell, Sara, von Schantz, Laura, Thagesson, Mia, Werchau, Doreen, Smedenfors, Kristine, Johansson, Maria, Rosén, Anna, Åberg, Ida, Winnerstam, Magnus, Nyblom, Eva, Barchan, Karin, Furebring, Christina, Norlén, Per, Ellmark, Peter
Publicado 2019